The association of historical opioid use with health care use and death among patients with chronic obstructive pulmonary disease (COPD) has been tested. Using Mississippi Medicaid data, we examined the association of transient or short-term opioid use and acute respiratory exacerbations among adults with COPD. We used a case-crossover design and 2013–2017 Mississippi Medicaid administrative claims data. A total of 1,972 qualifying exacerbation events occurred in 1,354 beneficiaries. The frequency and dose of opioid exposure in the 7 days before the exacerbation were examined and compared with the opioid exposure in 10 control windows, each 7 days long, before the exacerbation. Adjusted odds ratios were estimated using conditional logistic regression models to estimate the risk of opioid use on exacerbations after accounting for use of bronchodilators, corticosteroids, benzodiazepines, and β-blockers. Overall, opioid exposure in the 7 days before an exacerbation was significantly associated with acute respiratory exacerbation (odds ratio = 1.81; 95% confidence interval: 1.60, 2.05). Each 25-mg increase in morphine equivalent daily dose was associated with an 11.2% increase in the odds of an acute respiratory exacerbation (odds ratio = 1.11; 95% confidence interval: 1.04, 1.20). Transient use of opioids was significantly associated with acute respiratory exacerbation of COPD.
Endobronchial ultrasound (EBUS) and mediastinoscopy involve sampling thoracic lymph nodes to diagnose and stage lung cancer. These two procedures demonstrate similar diagnostic yield, although EBUS is a less invasive and more affordable sampling method. While clinical studies discuss differences in outcomes, there is limited data about EBUS adoption over the years and its impact on mediastinoscopy utilization. The objective of this study is to assess procedure trends and rates of post-procedural pneumothorax, an important potential complication of these procedures. Methods: The analysis was conducted with the Instant Health Data platform. Patients who underwent either EBUS or mediastinoscopy between 2009-2016 were identified in Medicare SAF 5% data. Relevant patient demographics were measured, including age, region, race, sex, and Elixhauser scores. Post-procedural pneumothorax rates over 3 days and 3-month preprocedural rates of chronic obstructive pulmonary disease (COPD) were also examined. Procedures were identified by CPT codes while diagnoses were identified by ICD-9/10 diagnosis codes. Results: During 2009-2016, 7,706 patients underwent EBUS while 3,944 patients underwent mediastinoscopy. No significant demographic differences were observed between the two cohorts. EBUS grew 19.3% compounded year-over-year (YoY), while mediastinoscopy was observed to decline by -9.6%. Pneumothorax rates for EBUS and mediastinoscopy were 2.4% and 14.1%, respectively, within the post-procedure period (p,0.01). These rates were generally consistent across years. Rates of pre-procedural COPD diagnoses were not statistically significantly different: 54.7% for EBUS and 61.9% for mediastinoscopy (p=0.08). Conclusions: These results suggest a growth in the use of EBUS alongside a reduction in the use of mediastinoscopy among patients undergoing thoracic lymph node sampling for lung cancer. This trend may be explained by published clinical data, which demonstrates EBUS is an equally effective and less invasive procedure. Rates of post-procedural pneumothorax were also consistently higher among mediastinoscopy patients, which is not explained by differences in pre-procedural COPD status.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.